Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance) Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009
Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002) Bashey, Asad , Owzar, Kouros , Johnson, Jeffrey L. ... - - Biol. Blood Marrow Transplant. - 2011 Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100002
A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502 Devine, S. M. , Owzar, K. , Blum, W. , Deangelo, D. , Stone, R. M. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502 Devine, Steven M. , Owzar, Kouros , Blum, William , Mulkey, Flora ... - - J. Clin. Oncol - 2015 Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103
A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study Farag, S. , Owzar, K. , Hars, V. , Lazarus, H. M. , Stadtmauer, E. A. ... - ASH - Blood - 2009 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100101
Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events Mccarthy, P. L. , Linker, C. , Hofmeister, C. C. , Owzar, K. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Preliminary Analysis - Transplant - CALGB-100104
Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104 Mccarthy, P. L. , Owzar, K. , Anderson, K. C. , Hofmeister, C. C. ... - - Blood - 2010 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100104
Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients (Pts) with advanced indolent NHL and CLL: CALGB 109901 Shea, T. C. , Johnston, J. , Walsh, W. , Farag, S. , Mccarty, J. ... - - Blood - 2007 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-109901
Reduced Intensity Allogeneic Transplantation Provides High Event-Free And Overall Survival In Patients With Advanced Indolent B Cell Malignancies: CALGB 109901 Shea, Thomas , Johnson, Jeffrey , Westervelt, Peter , Farag, Sherif ... - - Biol Blood Marrow Transplant - 2011 Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-109901
CALGB 100801 (Alliance): A phase II multi-center study of the addition of azacitidine (AZA) following allogeneic transplantation using a targeted busulfan based conditioning regimen for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML) Vij, Ravi , Hars, Vera , Blum, William , Shore, Tsiporah ... - EBMT - Bone Marrow Transplantation - 2015 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100801
CALGB 100801 (Alliance): A phase II multi-center NCI cooperative group study of the addition of azacitidine (AZA) to reduced-intensity conditioning (RIC) allogeneic transplantation for high risk myelodysplasia (MDS) and older patients with acute myeloid leukemia (AML): Results of a busulfan test dose strategy Vij, Ravi , Hars, Vera , Shea, Thomas , Hoke, Eva , Blum, William ... - ASH - Blood - 2014 Abstract - Secondary Endpoint - Primary Analysis - Transplant - CALGB-100801
A phase II multi-center study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplantation for high-risk myelodysplasia (and older patients with acute myeloid leukemia: CALGB 100801 (Alliance). Vij, Ravi , Le-Rademacher, Jennifer , Laumann, Kristina , Hars, Vera ... - - Biol. Blood Marrow Transplant. - 2019 Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100801
